Antazida - Therapieprinzip mit breitem Wirkspektrum

Literaturangaben

[1] Nauert C, Jettka W: Überblick über die relevanten antaciden Verbindungen. In: Halter F (Hrsg.): Therapeutische Möglichkeiten bei Erkrankungen des oberen Gastrointestinaltraktes: Antazida im Blickpunkt. Vieweg: Braunschweig 1992; 11-22.

[2] Ali S: Vergleichende in-vitro-Untersuchungen von Antacida. Pharm Ztg 1982; 28:1482-9.

[3] Trapp, E.: Antacida und ihre Bedeutung bei der Behandlung gastroduodenaler Läsionen. Medikamentum 1991; 32(5):112-121.

[4] BfArM-Monographie Hydrotalcit: BAnz v. 28.04.1993.

[5] Fordtran JS, Morawski SG, Richardson CT: In vivo and in vitro evaluation of liquid antacids. N Engl J Med 1973 May 3; 288(18):923-8.(Medline)

[6] Nauert, Ch: Neue pharmakologische Aspekte der Antacida. In: Rösch W, Nauert C: Der Einsatz von Antazida in der Gastroenterologie. Vieweg: Braunschweig 1995; 24-35.

[7] Schnekenburger, J: Struktur und In vitro-Testung von Antazida. Z Gastroenterol (Suppl 1) 1988; 26:1-11.

[8] Plachy J, Antal I, Racz I, Kulcsar-Molnar Z, Muskath Z: In vitro biopharmaceutical investigation of antacid activity in standard dissolution test apparatus. Acta Pharm Hung 1995 Jan; 65(1):23-6.(Medline)

[9] Supplement: Moderne Antazida: Die Qualität muss stimmen. Dtsch Apoth Ztg 2001; 141(20):6.

[10] Richardson CT, Peterson WL: Clinical Pharmacology of Antacids. In: Bianchi-Porro G, Richardson CT (eds.): Antacids in Peptic Ulcer Disease. Raven: New York 1988; 3-16.

[11] siehe [10] a.a.O.

[12] Decktor DL, Robinson M, Gottlieb S: Comparative Effects of Liquid Antacids on Esophageal and Gastric pH in Patients with Heartburn. Am J Ther 1995 Jul; 2(7):481-486.(Medline)

[13] Robinson M: Drugs, bugs, and esophageal pH profiles. Yale J Biol Med 1999 Mar-Jun; 72(2-3):169-72.(Medline)

[14] Robert A, Nezamis JE, Lancaster C, Hanchar AJ: Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology 1979 Sep; 77(3):433-43.(Medline)

[15] siehe [5].

[16] Bauerfeind P, Cilluffo T, Armstrong D, Emde C, Muller-Duysing W, Duroux P, Blum AL: Fate of antacid gel in the stomach. Site of action and interaction with food. Dig Dis Sci 1990 May; 35(5):553-8.(Medline)

[17] Hoogerwerf WA, Pasriche PJ: Agents used for control of gastric acidity and treatment of peptic ulcers and Gastroesophageal Reflux Disease. In: Goodman and Gilman’s - The Pharmacological Basis of Therapeutics, McMillan: New York 2001; 1003-20.

[18] Lind T, Havelund T, Carlsson R, Anker-Hansen O, Glise H, Hernqvist H, Junghard O, Lauritsen K, Lundell L, Pedersen SA, Stubberod A: Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997 Oct; 32(10):974-9.(Medline)

[19] Steinbach J, Fass R, Mittal RK: Assessment of relationship between acid reflux and heartburn using receiver operating characteristic curves. Gastroenterol Clin North Am 2002 Dec; 31(4 Suppl):S45-58.(Medline)

[20] McColl KE: Helicobacter pylori-negative ulcer disease. J Gastroenterol 2000; 35(Suppl 12):47-50.(Medline)

[21] Hojgaard L, Mertz Nielsen A, Rune SJ: Peptic ulcer pathophysiology: acid, bicarbonate, and mucosal function. Scand J Gastroenterol Suppl 1996; 216:10-5.(Medline)

[22] Weberg R, Berstad A, Osnes M: Comparison of low-dose antacids, cimetidine, and placebo on 24-hour intragastric acidity in healthy volunteers. Dig Dis Sci 1992 Dec; 37(12):1810-4.(Medline)

[23] Mach T, Bogdal J: Low-dose antacids versus ranitidine in the shortterm treatment of patients with duodenal ulcer. Endoscopic and histologic placebo-controlled study. Mater Med Pol 1992 Jul-Sep; 24(3):201-4.(Medline)

[24] Zaterka S, Cordeiro F, Lyra LG, Toletino MM, Miszputen SJ, Jorge JL, Silva EP, Vieira FE, Modena JL, Massuda HK, et al: Very-low dose antacid in treatment of duodenal ulcer. Comparison with cimetidine. Dig Dis Sci 1991 Oct; 36(10):1377-83.(Medline)

[25] Caspary WF, Hengels KJ, Kunert H, Rosch W, Rohner HG, Spuhler S, Nauert C: Low-dose antacid therapy in the treatment of duodenal ulcer - a multicentre double-blind trial vs. misoprostol. Z Gastroenterol 1991 Sep; 29(9):411-6.(Medline)

[26] Boyle JM, Neiderhiser DH, Dworken HJ: Duodenogastric reflux in patients with gastric ulcer disease. J Lab Clin Med 1984 Jan; 103(1):14-21.(Medline)

[27] Zytotoxizität von Gallensäuren und Lysolecithin--ein Faktor in der Pathogenese des Ulcus ventriculi? Z Gastroenterol 1987 Aug; 25(Suppl 3):22-32.(Medline)

[28] Vaezi MF, Richter JE: Duodenogastro-oesophageal reflux. Baillieres Best Pract Res Clin Gastroenterol 2000 Oct; 14(5):719-29.(Medline)

[29] Yumiba T, Kawahara H, Nishikawa K, Inoue Y, Ito T, Matsuda H: Impact of esophageal bile exposure on the genesis of reflux esophagitis in the absence of gastric acid after total gastrectomy. Am J Gastroenterol 2002; 97(7):156-161.(Medline)

[30] DeMeester SR: Management of Barrett’s esophagus free of dysplasia. Semin Thorac Cardiovasc Surg 1997 Jul; 9(3):279-84.(Medline)

[31] Stamp, D: Bile acids and esophageal cancer. Gastroenterology 2003; 123:1024.(Medline)

[32] Taha AS, Angerson WJ, Morran CG: Reflux and Barrett’s oesophagitis after gastric surgery: Long-term follow-up an implicationsfor the roles of gastric acid and bile in oesophagitis. Aliment Pharmacol Ther 2003; 17:547-552.(Medline)

[33] Guthauser UJ, Hacki WH: Bindung von Gallensalzen und Lysolecithin in physiologischen Medien durch verschiedene Antazida. Schweiz Med Wochenschr 1987 Feb 28; 117(9):322-7.(Medline)

[34] Shiau YF, Schenkein JP, Liu HJ, Khouri MR, Watkins JB: Bile salt binding properties of commonly used gastrointestinal drugs: maalox, carafate, and questran. J Pharm Sci 1988 Jun; 77(6):527-30.(Medline)

[35] Kurtz W, Güldütuna S, Leuschner U: Gallensäurenbindung durch Antazida in "quasi-natürlichem" Refluxmilieu. Z Gastroenterol 1989 Jul; 27(7):370-3.

[36] Kurtz W, Güldütuna S, Leuschner U: The effect of pH and amount of antacids on bile acid binding in a quasi-natural reflux milieu. Z Gastroenterol 1991 May; 29(5):237-41.

[37] Güldütuna S: Gallensäureadsorption durch Antazida. In: Halter F (Hrsg.): Therapeutische Möglichkeiten bei Erkrankungen des oberen Gastrointestinaltraktes: Antazida im Blickpunkt. Vieweg: Braunschweig 1992; 11-22.

[38] Stahlberg M, Jalovaara P, Laitinen S, Mokka R, Hentila R, Jarvensivu P, Kairaluoma M: Adsorption of bile acids by sucralfate, antacids, and cholestyramine in vitro. Clin Ther 1987; 9(6):615-21.(Medline)

[39] Mangnall YF, Smythe A, Johnson AG: The ability of antacids and cholestyramine to bind bile acids: effect of pH. Scand J Gastroenterol 1986 Sep; 21(7):789-94.(Medline)

[40] siehe [14].

[41] siehe [14].

[42] Hollander D, Tarnawski A, Gergely H: Protection against alcohol-induced gastric mucosal injury by aluminum-containing compounds - sucralfate, antacids, and aluminum sulfate. Scand J Gastroenterol Suppl 1986; 125:151-5.(Medline)

[43] Konturek SJ, Radecki T, Piastucki I, Brzozowski T, Drozdowicz D: Gastrocytoprotection by colloidal bismuth subcitrate (De-Nol) and sucralfate. Role of endogenous prostaglandins. Gut 1987 Feb; 28(2):201-5.(Medline)

[44] Hollander D, Tarnawski A: Are antacids cytoprotective? Gut 1989 Feb; 30(2):145-7.(Medline)

[45] siehe [42].

[46] Tarnawski A, Hollander D, Gergely H: Antacids: new perspectives in cytoprotection. Scand J Gastroenterol Suppl 1990; 174:9-14.(Medline)

[47] Konturek SJ, Brzozowski T, Drozdowicz D, Nauert C: Gastroprotection by an aluminium- and magnesium hydroxide-containing antacid in rats. Role of endogenous prostanoids. Scand J Gastroenterol 1989 Nov; 24(9):1113-20.(Medline)

[48] Brzozowski T, Konturek SJ, Majka J, Drozdowicz D, Pytko-Polonczyk J, Nauert C: Supralox: a novel aluminium containing antacid with gastroprotective and ulcer healing activity. Eur J Gastroenterol Hepatol 1993; 5(3):165-71.

[49] al Gohary OM, el Din K, el Tahir H: Formulation of aspirin-magaldrate double-layer tablets: in vitro evaluation and cytoprotective activity in rats. Boll Chim Farm 1996 Jul-Aug; 135(7):421-8.(Medline)

[50] DiJoseph JF, Borella LE, Mir GN: Activated aluminum complex derived from solubilized antacids exhibits enhanced cytoprotective activity in the rat. Gastroenterology 1989 Mar; 96(3):730-5.(Medline)

[51] Konturek SJ, Brzozowski T, Drozdowicz D, Nauert C: Role of intragastric pH in cytoprotection by antacids in rats. Eur J Pharmacol 1990 Feb 6; 176(2):187-95.(Medline)

[52] siehe [47].

[53] siehe [50].

[54] siehe [51].

[55] Preclik G, Stange EF, Gerber K, Fetzer G, Horn H, Ditschuneit H: Alimentary tract and pancreas. Stimulation of mucosal prostaglandin synthesis in human stomach and duodenum by antacid treatment. Gut 1989 Feb; 30(2):148-51.(Medline)

[56] siehe [47].

[57] Vergin H, Kori-Lindner C: Putative mechanisms of cytoprotective effect of certain antacids and sucralfate. Dig Dis Sci 1990 Nov; 35(11):1320-7.(Medline)

[58] Preclik G, Stange EF, Gerber K, Fetzer G, Horn H, Schneider A, Ditschuneit H: Effect of antacid treatment on endogenous prostaglandin synthesis in human antral and duodenal mucosa. Dig Dis Sci 1989 Dec; 34(12):1860-4.(Medline)

[59] Konturek SJ, Kwiecien N, Obtulowicz W, Hebzda Z, Oleksy J: Effects of protective drugs on gastric alkaline secretion in man. Scand J Gastroenterol 1987 Nov; 22(9):1059-63.(Medline)

[60] Florent C, Desaint B, Legendre C, Chappuis P, Galle C, Giboudeau J, de Meynard C: Morphologic and ultrastructural effects of Maalox TC on human gastric and duodenal mucosa. J Clin Gastroenterol 1991; 13(Suppl 1):S139-44.(Medline)

[61] siehe [57].

[62] Patel AV, Santani DD, Goyal RK: Antiulcer activity and the mechanism of action of magaldrate in gastric ulceration models of rat. Indian J Physiol Pharmacol 2000 Jul; 44(3):350-4.(Medline)

[63] Konturek SJ, Brzozowski T, Majka J, Szlachcic A, Nauert C, Slomiany B: Nitric oxide in gastroprotection by aluminium-containing antacids. Eur J Pharmacol 1992 Dec 15; 229(2-3):155-62.(Medline)

[64] Sewing KF: Efficacy of low-dose antacids in the treatment of peptic ulcers: pharmacological explanation? J Clin Gastroenterol 1991; 13(Suppl 1):S134-8.(Medline)

[65] Konturek SJ, Brzozowski T, Drozdowicz D, Dembinski A, Nauert C: Healing of chronic gastroduodenal ulcerations by antacids. Role of prostaglandins and epidermal growth factor. Dig Dis Sci 1990 Sep; 35(9):1121-9.(Medline)

[66] siehe [64].

[67] siehe [35].

[68] Tarnawski, A, Douglas, TG, Ishikawa, T, Gergely, H: Does Antacid provide better quality of experimental gastric ulcer healing than omeprazole? Gastroenterology 1992; 102(5):A 175.

[69] Tarnawski AS, Tomikawa M, Ohta M, Sarfeh IJ: Antacid talcid activates in gastric mucosa genes encoding for EGF and its receptor. The molecular basis for its ulcer healing action. J Physiol Paris 2000 Mar-Apr; 94(2):93-8.(Medline)

[70] Folkman J, Szabo S, Stovroff M, McNeil P, Li W, Shing Y: Duodenal ulcer. Discovery of a new mechanism and development of angiogenic therapy that accelerates healing. Ann Surg 1991 Oct; 214(4):414-25; discussion 426-7.(Medline)

[71] Graham DY: Helicobacter pylori infection is the primary cause of gastric cancer. J Gastroenterol 2000; 35 Suppl 12:90-7.(Medline)

[72] Yang JC, Lin BR, Wang JT, Chen WH, Lin JT, Wang TH: The role of gastric acid and Helicobacter pylori in the natural course of duodenal ulcer. J Microbiol Immunol Infect 1999 Sep; 32(3):155-62.(Medline)

[73] Queiroz DM, Rocha GA, Oliveira CA, Rocha AM, Santos A, Cabral MM, Nogueira AM: Role of corpus gastritis and cagA-positive Helicobacter pylori infection in reflux esophagitis. J Clin Microbiol 2002 Aug; 40(8):2849-53.(Medline, Volltext)

[74] Andersen LP: Cytoprotective agents and C. pylori associated acid peptic diseases. Scand J Gastroenterol Suppl 1988; 142:110-3.(Medline)

[75] Berstad K, Weberg R, Berstad A: Suppression of gastric urease activity by antacids. Scand J Gastroenterol 1990 May; 25(5):496-500.(Medline)

[76] Kamiya S, Yamaguchi H, Osaki T, Taguchi H, Fukuda M, Kawakami H, Hirano H: Effect of an aluminum hydroxide-magnesium hydroxide combination drug on adhesion, IL-8 inducibility, and expression of HSP60 by Helicobacter pylori. Scand J Gastroenterol 1999 Jul; 34(7):663-70.(Medline)

[77] Tarnawski A, Pai R, Itani R, Wyle FA: The antacid Talcid adsorbs and neutralizes all proteins secreted by H. pylori including VacA cytotoxin: a new mechanism for its ulcer-healing action? Digestion 1999 Sep-Oct; 60(5):449-55.(Medline)

[78] Caputo R, Tuccillo C, Manzo BA, Zarrilli R, Tortora G, Blanco Cdel V, Ricci V, Ciardiello F, Romano M: Helicobacter pylori VacA Toxin Up-Regulates Vascular Endothelial Growth Factor Expression in MKN 28 Gastric Cells through an Epidermal Growth Factor Receptor-, Cyclooxygenase-2-dependent Mechanism. Clin Cancer Res 2003 Jun; 9(6):2015-21.(Medline)

[79] Faaij RA, Van Gerven JM, Jolivet-Landreau I, Masclee AA, Vendrig EM, Schoemaker RC, Jacobs LD, Cohen AF: Onset of action during on-demand treatment with maalox suspension or low-dose ranitidine for heartburn. Aliment Pharmacol Ther 1999 Dec; 13(12):1605-10.(Medline)

[80] Miederer, SE, Nauert C: Behandlung säurebedingter Oberbauchschmerzen nach H.-pylori-Eradikation: Erste Ergebnisse mit einem Antazidum. J Pharmakol Ther 2003; 12(4):103-110.

[81] O’Leary C, McCarthy J, Humphries M, Shanahan F, Quigley E: The prophylactic use of a proton pump inhibitor before food and alcohol. Aliment Pharmacol Ther 2003; 17:683-686.(Medline)

[82] Hürlimann S, Michel K, Inauen W, Halter F: Effect of Rennie Liquid versus Maalox Liquid on intragastric pH in a double-blind, randomized, placebo-controlled, triple crossover study in healthy volunteers. Am J Gastroenterol 1996 Jun; 91(6):1173-80.(Medline)

[83] Maton PN, Burton ME: Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use. Drugs 1999 Jun; 57(6):855-70.(Medline)

[84] Berstad A, Weberg R: Antacids in the treatment of gastroduodenal ulcer. Scand J Gastroenterol 1986 May; 21(4):385-91.(Medline)

[85] Walan A: Antacids and anticholinergics in the treatment of duodenal ulcer. Clin Gastroenterol 1984 May; 13(2):473-99.(Medline)

[86] Berstad A, Weberg R: Antacids for peptic ulcer: do we have anything better? Scand J Gastroenterol (Suppl) 1986; 125:32-41.(Medline)

[87] Lux G, Hentschel H, Rohner HG, Brunner H, Schütze K, Lederer PC, Rösch W: Treatment of duodenal ulcer with low-dose antacids. Scand J Gastroenterol 1986 Nov; 21(9):1063-8.(Medline)

[88] siehe [25].

[89] Bosseckert H, Caspary WF, Stolte M, Nauert C und die PUMA-(Pain-Ulcer-Maalox-Studie)Studiengruppe: Niedrig dosierte Antazidatherapie zur Behandlung des Ulcus duodeni. Verdauungskrankheiten 1996; 2(14):50-5.

[90] siehe [79].

[91] siehe [80].

[92] Bosseckert, H: Aluminium-magnesiumhydroxidhaltige Antazida. Der deutsche Apotheker 1998; 50(10):261-2.

[93] Loch EG, Leiss O: Sodbrennen in der Schwangerschaft - nur ein Symptom? Gynäkol Prax 2002; 26:219-26.

[94] Martin LF: Stress ulcers are common after aortic surgery. Endoscopic evaluation of prophylactic therapy. Am Surg 1994 Mar; 60(3):169-74.(Medline)

[95] Kentrup H, Skopnik H, Wolter L, Engelhart W, Nauert C, Heimann G: Antazida zur postoperativen Streßulkusprophylaxe bei Säuglingen: Studie zur Dosisfindung. Klin Pädiatr 1996 Jan-Feb; 208(1):14-6.(Medline)